Thursday, January 17, 2013
Washington University in St. Louis School of Medicine
researchers have used next-generation sequencing to identify mutations in HER2 that are missed by
standard screening tests that identify only amplifications.1 Based
on the findings, the researchers are now recruiting patients with breast cancer
expressing the mutations for a Phase II trial of Puma Biotechnology Inc.'s
HER2-targeting compound, neratinib.
Fulmer, T. SciBX 6(2); doi:10.1038/scibx.2013.26
Published online Jan. 17, 2013
1. Bose, R. et al.
Cancer Discov.; published online Dec. 7, 2012;
Contact: Ron Bose, Washington University in St. Louis School of
Medicine, St. Louis, Mo.
Contact: Matthew J. Ellis, same affiliation as above
2. Owens, M.A. et al.
Clin. Breast Cancer 5, 63-69 (2004)
2. Ellis, M.J. et al.
Nature 486, 353-360 (2012)
3. Lee, J.W. et al.
Clin. Cancer Res. 12, 57-61 (2006)
4. Shah, S.P. et al.
Nature 461, 809-813 (2009)
5. Shah, S.P. et al.
Nature 486, 395-399 (2012)
AND INSTITUTIONS MENTIONED
American Cancer Society, Atlanta, Ga.
Dana-Farber Cancer Institute, Boston, Mass.
Genentech Inc., South San Francisco, Calif.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Puma Biotechnology Inc. (NYSE:PBYI), Los Angeles, Calif.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
The University of North Carolina at Chapel Hill, Chapel Hill, N.C.
Washington University in St. Louis School of Medicine, St. Louis, Mo.